vs
Orthofix Medical Inc.（OFIX）与QUALYS, INC.（QLYS）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是QUALYS, INC.的1.3倍（$219.9M vs $175.3M），QUALYS, INC.净利率更高（30.3% vs -1.0%，领先31.3%），QUALYS, INC.同比增速更快（10.1% vs 2.0%），QUALYS, INC.自由现金流更多（$74.9M vs $16.8M），过去两年QUALYS, INC.的营收复合增速更高（9.6% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Qualys是总部位于美国加利福尼亚州福斯特城的科技企业，专注于云安全、合规管理及相关服务，为客户提供覆盖云环境的安全防护与合规解决方案，助力企业应对各类网络安全风险，满足不同行业的合规运营需求。
OFIX vs QLYS — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$175.3M
营收增速更快
QLYS
高出8.1%
2.0%
净利率更高
QLYS
高出31.3%
-1.0%
自由现金流更多
QLYS
多$58.1M
$16.8M
两年增速更快
QLYS
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $175.3M |
| 净利润 | $-2.2M | $53.1M |
| 毛利率 | 71.1% | 83.4% |
| 营业利润率 | 0.2% | 33.6% |
| 净利率 | -1.0% | 30.3% |
| 营收同比 | 2.0% | 10.1% |
| 净利润同比 | 92.4% | 20.9% |
| 每股收益（稀释后） | $-0.05 | $1.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXQLYS
| Q4 25 | $219.9M | $175.3M | ||
| Q3 25 | $205.6M | $169.9M | ||
| Q2 25 | $203.1M | $164.1M | ||
| Q1 25 | $193.6M | $159.9M | ||
| Q4 24 | $215.7M | $159.2M | ||
| Q3 24 | $196.6M | $153.9M | ||
| Q2 24 | $198.6M | $148.7M | ||
| Q1 24 | $188.6M | $145.8M |
净利润OFIXQLYS
| Q4 25 | $-2.2M | $53.1M | ||
| Q3 25 | $-22.8M | $50.3M | ||
| Q2 25 | $-14.1M | $47.3M | ||
| Q1 25 | $-53.1M | $47.5M | ||
| Q4 24 | $-29.1M | $44.0M | ||
| Q3 24 | $-27.4M | $46.2M | ||
| Q2 24 | $-33.4M | $43.8M | ||
| Q1 24 | $-36.0M | $39.7M |
毛利率OFIXQLYS
| Q4 25 | 71.1% | 83.4% | ||
| Q3 25 | 72.2% | 83.6% | ||
| Q2 25 | 68.7% | 82.4% | ||
| Q1 25 | 62.8% | 81.9% | ||
| Q4 24 | 69.0% | 81.8% | ||
| Q3 24 | 68.7% | 81.3% | ||
| Q2 24 | 67.8% | 82.2% | ||
| Q1 24 | 67.5% | 81.3% |
营业利润率OFIXQLYS
| Q4 25 | 0.2% | 33.6% | ||
| Q3 25 | -8.3% | 35.3% | ||
| Q2 25 | -7.9% | 31.3% | ||
| Q1 25 | -25.2% | 32.4% | ||
| Q4 24 | -5.3% | 31.0% | ||
| Q3 24 | -9.6% | 29.2% | ||
| Q2 24 | -12.5% | 32.3% | ||
| Q1 24 | -15.6% | 30.7% |
净利率OFIXQLYS
| Q4 25 | -1.0% | 30.3% | ||
| Q3 25 | -11.1% | 29.6% | ||
| Q2 25 | -6.9% | 28.8% | ||
| Q1 25 | -27.4% | 29.7% | ||
| Q4 24 | -13.5% | 27.6% | ||
| Q3 24 | -13.9% | 30.0% | ||
| Q2 24 | -16.8% | 29.4% | ||
| Q1 24 | -19.1% | 27.2% |
每股收益（稀释后）OFIXQLYS
| Q4 25 | $-0.05 | $1.47 | ||
| Q3 25 | $-0.57 | $1.39 | ||
| Q2 25 | $-0.36 | $1.29 | ||
| Q1 25 | $-1.35 | $1.29 | ||
| Q4 24 | $-0.76 | $1.19 | ||
| Q3 24 | $-0.71 | $1.24 | ||
| Q2 24 | $-0.88 | $1.17 | ||
| Q1 24 | $-0.95 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $250.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $561.2M |
| 总资产 | $850.6M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXQLYS
| Q4 25 | $82.0M | $250.3M | ||
| Q3 25 | $62.9M | $225.3M | ||
| Q2 25 | $65.6M | $194.0M | ||
| Q1 25 | $58.0M | $290.7M | ||
| Q4 24 | $83.2M | $232.2M | ||
| Q3 24 | $30.1M | $235.4M | ||
| Q2 24 | $26.4M | $281.2M | ||
| Q1 24 | $27.0M | $273.8M |
总债务OFIXQLYS
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXQLYS
| Q4 25 | $450.0M | $561.2M | ||
| Q3 25 | $442.5M | $529.4M | ||
| Q2 25 | $458.3M | $508.2M | ||
| Q1 25 | $458.3M | $498.0M | ||
| Q4 24 | $503.1M | $477.1M | ||
| Q3 24 | $525.9M | $449.6M | ||
| Q2 24 | $546.0M | $427.8M | ||
| Q1 24 | $570.3M | $404.2M |
总资产OFIXQLYS
| Q4 25 | $850.6M | $1.1B | ||
| Q3 25 | $832.6M | $1.0B | ||
| Q2 25 | $837.2M | $999.5M | ||
| Q1 25 | $823.1M | $996.5M | ||
| Q4 24 | $893.3M | $973.5M | ||
| Q3 24 | $867.9M | $908.3M | ||
| Q2 24 | $882.0M | $876.6M | ||
| Q1 24 | $906.0M | $861.8M |
负债/权益比OFIXQLYS
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $75.7M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $74.9M |
| 自由现金流率自由现金流/营收 | 7.6% | 42.8% |
| 资本支出强度资本支出/营收 | 4.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.42× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $304.4M |
8季度趋势，按日历期对齐
经营现金流OFIXQLYS
| Q4 25 | $27.7M | $75.7M | ||
| Q3 25 | $12.4M | $90.4M | ||
| Q2 25 | $11.6M | $33.8M | ||
| Q1 25 | $-18.4M | $109.6M | ||
| Q4 24 | $23.7M | $47.7M | ||
| Q3 24 | $11.7M | $61.0M | ||
| Q2 24 | $9.0M | $49.8M | ||
| Q1 24 | $-18.6M | $85.5M |
自由现金流OFIXQLYS
| Q4 25 | $16.8M | $74.9M | ||
| Q3 25 | $2.5M | $89.5M | ||
| Q2 25 | $4.5M | $32.4M | ||
| Q1 25 | $-25.1M | $107.5M | ||
| Q4 24 | $15.2M | $41.9M | ||
| Q3 24 | $6.3M | $57.6M | ||
| Q2 24 | $-360.0K | $48.8M | ||
| Q1 24 | $-29.1M | $83.5M |
自由现金流率OFIXQLYS
| Q4 25 | 7.6% | 42.8% | ||
| Q3 25 | 1.2% | 52.7% | ||
| Q2 25 | 2.2% | 19.8% | ||
| Q1 25 | -13.0% | 67.3% | ||
| Q4 24 | 7.0% | 26.3% | ||
| Q3 24 | 3.2% | 37.4% | ||
| Q2 24 | -0.2% | 32.8% | ||
| Q1 24 | -15.4% | 57.2% |
资本支出强度OFIXQLYS
| Q4 25 | 4.9% | 0.4% | ||
| Q3 25 | 4.8% | 0.5% | ||
| Q2 25 | 3.5% | 0.8% | ||
| Q1 25 | 3.5% | 1.3% | ||
| Q4 24 | 4.0% | 3.7% | ||
| Q3 24 | 2.7% | 2.2% | ||
| Q2 24 | 4.7% | 0.7% | ||
| Q1 24 | 5.6% | 1.4% |
现金转化率OFIXQLYS
| Q4 25 | — | 1.42× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 2.31× | ||
| Q4 24 | — | 1.09× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | — | 2.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
